START FREE TRIAL

Nike’s China Slump Is Starting to Look Like Something More!

AI Summary

🔒 UNLOCK AI SUMMARY WITH FREE TRIAL

START FREE TRIAL

Nike (NYSE:NKE) has spent years selling the idea that great brands travel well. In China, that assumption is starting to break. Put the swoosh on a shoe, add elite athletes, tighten distribution, and the formula should work almost anywhere.

That logic now looks less reliable in China. The latest quarter did not just show weak demand. It showed a global brand confronting a market that no longer treats foreign scale as a built-in advantage.

China revenue fell for a seventh straight quarter, and management guided for roughly a 20% drop in the current quarter. At the same time, Nike said the issue is not only cyclical.

It called out “structural challenges,” reduced sell-in on purpose, and kept cleaning up inventory to protect full-price demand. That changes the conversation.

This is no longer just a turnaround story. It is also a story about whether the old globalization playbook still works when local brands move faster, price sharper, and feel closer to the consumer.

The China Slowdown Looks Structural, Not Seasonal

Nike’s China weakness now reads like a pattern, not a pause. The company has posted seven straight quarters of declining sales in the region, and management expects…

Continue Reading With Our 7-Day Free Trial

ONLY $10 per month after the trial. Cancel anytime. No sponsors. No conflicts. 100% independent stock research.

Recent Articles

SpaceX: Is Elon Musk’s AI Empire Turning Into Wall Street’s Biggest Debt Test?

Twelve days after SpaceX raised $86 billion in the...

AI Trade Has Its First MAJOR CRACK as KOSPI Crashes 10%!

South Korea's stock market just had its worst day...

Alphabet: The $225 Billion AI Talent Shock Wall Street Cannot Ignore

Alphabet Inc. (NASDAQ:GOOGL) just gave Wall Street a reminder...

Micron Reports in 48 Hours. The Number Everyone Is Watching Isn’t the EPS.

Micron Technology reports earnings on Wednesday evening. The stock is...

AbbVie’s $11 Billion Eczema Gamble Is Bigger Than Skin

AbbVie Inc. (NYSE:ABBV) may be close to buying Apogee...

Related Articles

AI Trade Has Its First MAJOR CRACK as KOSPI Crashes 10%!

South Korea's stock market just had its worst day...

Alphabet: The $225 Billion AI Talent Shock Wall Street Cannot Ignore

Alphabet Inc. (NASDAQ:GOOGL) just gave Wall Street a reminder...

Micron Reports in 48 Hours. The Number Everyone Is Watching Isn’t the EPS.

Micron Technology reports earnings on Wednesday evening. The stock is...

AbbVie’s $11 Billion Eczema Gamble Is Bigger Than Skin

AbbVie Inc. (NYSE:ABBV) may be close to buying Apogee...

The FTC Is Coming For Amazon’s Sponsored Ads

Amazon.com, Inc. (NASDAQ:AMZN) may have a new headache, and...

Moderna’s Flu Shot Won Over FDA Advisers—But Can It Win Back America?

Moderna (NASDAQ:MRNA) just landed a regulatory moment that people...

Did Fox Pay $25 Billion For Roku’s Platform, Or Its Ad Data Edge?

Fox Corp (NASDAQ:FOXA) has made its biggest swing yet...
spot_img

Related Articles

Popular Categories

spot_imgspot_img